Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation [4]

Blood

Volumn 109, Issue 9, 2007, Pages 4106-4107

  Hussein, Kais ^b   Bock, Oliver ^b   Seegers, Anna ^b   Flasshove, Michael ^b   Henneke, Felicitas ^b   Buesche, Guntram ^b   Kreipe, Hans Heinrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEMOGLOBIN; IMATINIB; JANUS KINASE 2; LACTATE DEHYDROGENASE;

ADULT; BONE MARROW; CASE REPORT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; GENE FREQUENCY; GENE MUTATION; HUMAN; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MEGAKARYOCYTE; MYELOFIBROSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SPLENOMEGALY;

EID: 34247397427     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-061135     Document Type: Letter

References (7)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
2. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G< T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
3. Bock O, Busche G, Koop C, Schroter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn. 2006;8:170-177.
4. V617F mutation in polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Ann Hematol. 2007;86:245-253.
5. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
6. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.
7. Kralovics R, Teo S-S, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.